603858 步长制药
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.9842.660-11.4768.29713.610
总资产报酬率 ROA (%)0.5401.489-6.6794.9728.445
投入资产回报率 ROIC (%)0.7312.021-8.8796.48310.386

边际利润分析
销售毛利率 (%)58.66368.15271.69173.78176.628
营业利润率 (%)8.0713.292-8.35710.28114.777
息税前利润/营业总收入 (%)9.0193.671-7.66410.95815.486
净利润/营业总收入 (%)3.3211.147-10.6417.03111.515

收益指标分析
经营活动净收益/利润总额(%)79.391258.509-135.174101.88991.822
价值变动净收益/利润总额(%)-1.9394.799-0.217-2.6720.662
营业外收支净额/利润总额(%)-1.295-10.5090.788-2.143-0.198

偿债能力分析
流动比率 (X)1.2561.2081.2921.1661.022
速动比率 (X)0.5350.4890.7470.6310.668
资产负债率 (%)46.87245.54944.08239.96739.654
带息债务/全部投入资本 (%)23.62920.70520.11719.062--
股东权益/带息债务 (%)308.856365.294379.042411.068397.511
股东权益/负债合计 (%)115.796122.075127.755149.940151.118
利息保障倍数 (X)8.5825.304-10.09312.27820.982

营运能力分析
应收账款周转天数 (天)45.31042.50037.21432.1390.000
存货周转天数 (天)408.487372.069324.192287.4930.000